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The coordinated regulation of chemokine responsiveness plays a
critical role in the development of humoral immunity. After anti-
gen challenge and B cell activation, the emerging plasma cells (PCs)
undergo CXCL12-induced chemotaxis to the bone marrow, where
they produce Ab and persist. Here we show that PCs, but not B cells
or T cells from lupus-prone NZM mice, are deficient in CXCL12-
induced migration. PC unresponsiveness to CXCL12 results in a
marked accumulation of PCs in the spleen of mice, and a concor-
dant decrease in bone marrow PCs. Unlike normal mice, in NZM
mice, a majority of the splenic PCs are long-lived. This deficiency is
a consequence of the genetic interactions of multiple systemic
lupus erythematosus susceptibility loci.
Long-lived humoral immune responses are a hallmark ofthymus-dependent (TD) immunity (1, 2). The cellular basis
for enduring Ab-mediated immunity is that of long-lived mem-
ory B cells and plasma cells (PCs). Both of these cell populations
acquire longevity as a result of antigen (Ag)-specific, cognate
interactions with helper T cells within germinal centers (GCs).
PC precursors that emerge from these GC reactions seed
the bone marrow (BM) and terminally differentiate to end-
stage Ab-secreting cells. Recent studies (3–6) have shown that
long-lived PCs predominantly reside in the BM and can produce
Abs for months, or even years, after initial Ag exposure. The
importance of long-lived PCs is underscored by the classic
studies by Benner and colleagues (7, 8), who established that up
to 80% of the serum Ig produced is derived from BM PCs.
The specific microenvironment occupied by PCs has been
implicated as a determinant in cellular lifespan, survival, and,
hence, the capacity to produce Ig for long periods of time (2, 9,
10). Migration to specific microenvironmental niches is con-
trolled by chemokines and their receptors. It is known that
chemokines control the coordinated migration of Ag-reactive B
cells to precise anatomical locations within secondary lymphoid
organs and between lymphoid compartments. Studies have
firmly established that B cell homing to follicles, periarteriolar
lymphoid sheath, and the red pulp in spleen is orchestrated by
the action of specific chemokines and their receptors. B cell entry
into the follicles depends on the expression of CXCR5 by B cells,
and by binding its ligand, CXCL13, which is produced by
follicular dendritic cells (11, 12). After activation within the GC,
the expression of CXCR5 and the CCL19 receptor (presumably
CCR7) is reduced, relieving the GC retention of activated B cells
(13). Concordant with this reduced GC retention, the activity of
CXCR4 is enhanced and facilitates the departure of activated B
cells from the GC. CXCL12, the ligand for CXCR4, is produced
by BM stromal cells and guides the recruitment of postGC B cells
to the BM (13–15). Having reached the BM, this environment
supports the terminal differentiation and longevity of PCs.
Long-lived, affinity-matured humoral immune responses are
essential for enduring protection of the host from pathogens.
However, the persistent production of pathogenic autoAbs by
the host mediates the chronic, destructive clinical manifestations
of Ab-mediated autoimmune diseases, like systemic lupus ery-
thematosus (SLE) (16–19). This article addresses the behavior of
postGC B cells and PCs in a murine model of SLE. Contrary to
the behavior of normal long-lived PCs, we show here that PCs
from NZM2410 mice do not migrate to the BM, and, as such,
accumulate in the spleen. Unexpectedly, although these patho-
genic PCs are restricted to the splenic environment, the vast
majority of them are long-lived. Based on ex vivo migration
studies, a loss in responsiveness of NZM PCs to CXCL12, is at
least one mechanism responsible for the lack of BM homing.
Furthermore, we report that defective CXCL12-induced migra-
tion is not a trait expressed by resting lymphocytes, but is an
acquired deficiency manifested by postGC B cells in the
NZM2410 strain. Whereas not all lupus-prone strains of mice
express this deficiency, this deficiency may contribute to the
aggressive nature of the disease found in the NZM2410 strain.
Evidence that this trait does cosegregate with disease is provided
by observations that loss in CXCL12 responsiveness is the result
of the interactions between Sle1, Sle2, and Sle3 susceptibility loci.
Materials and Methods
Mice. Ten- to 12-week old NZM2410 (Taconic Farms), C57BL6,
MRLlpr/lpr, BXSB, New Zealand white (NZW), New Zealand
black (NZB), and Rag1/ (The Jackson Laboratory) mice were
maintained in the specific pathogen-free animal facility at
Dartmouth Medical School. C57BL6 congenic strains carrying
the Sle1, Sle2, Sle3, and Sle123 susceptibility loci were generated
as described (20).
Immunization. Mice were challenged i.p. with 100 g of 4-hydroxy-
3-nitrophenylacetyl-keyhole limpet hemocyanin (NP36-KLH)
(Biosearch Technologies, Novato, CA) either emulsified in
complete Freund’s adjuvant (CFA) or CFA alone. For 2° re-
sponses, immune mice were rechallenged after 30 days with
100 g of NP36-KLH Alum, and analyses were performed after
an additional 30 days.
Enzyme-Linked Immunospot (ELISPOT) Assays. Spleen and BM IgG-
secreting cells were enumerated by an Ag-specific ELISPOT
assay as described (21). Plates were coated with calf thymus
single-stranded DNA (Sigma), NP25-BSA, or NP4-BSA (Bio-
search Technologies) to measure total and high-affinity Ag-
specific Abs. Data shown are the mean ( SD) values of three
mice per group and are representative of at least three inde-
pendent experiments.
Immunohistochemistry. Frozen spleen sections (5 m thick) were
acetone-fixed, and stained in 1% BSA PBS with fluorochrome-
coupled rat anti-mouse Abs. Samples were analyzed on a Bio-
Rad 1024 confocal microscope. Images are representative of
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three experiments with 30 scanned images of three mice per
group (objective magnification, 10).
Adoptive Transfer. NZM, NZB, and C57BL6 mice were immu-
nized with NP36-KLH CFA or NP32-Ficoll. After 10 or 30 days as
indicated, spleen and BM cells were T cell-depleted by using
anti-Thy1.2 plus anti-CD4 Ab and rabbit complement (Accurate
Chemicals, Westbury, NY), and transferred (20  106 cells) i.v. into
Rag1/ recipients. Initial PC numbers transferred from NZM,
NZB, and B6 mice were 3.8  105, 6.6  105, and 4.2  105,
respectively. As indicated, some recipients received splenic B cells
that were treated with 50 gml mitomycin C (Mito-C) (Sigma) in
PBS for 20 min at 37°C. After treatment, cells were washed and
viability was analyzed by Trypan blue exclusion. ELISPOT analyses
of recipients were performed 30 days posttransfer.
Abs and Reagents. Staining mAbs to B220, CD138, VLA-4,
CXCR4, and CD4 were purchased from Pharmingen. Strepta-
vidin-phycoerythrin (PE) and FITC were obtained from South-
ern Biotechnology Associates.
Migration Assays. To quantify PC chemotaxis, 3  106 spleen cells
were added to 5 m of microporous 6.5-mm transwell plates
(Corning), and were allowed to equilibrate in migration medium
(0.5% BSA10 mM Hepes10% FCS in RPMI medium 1640) for
1 h at 37°C. Recombinant mouse CXCL12 or CXCL13 (R & D
Systems) was added at 100 ngml to the wells, and cells were
cultured for an additional 2 h. Cells remaining in the inserts and
those that migrated to wells were collected, and flow cytometry
or ELISPOT analyses were performed. Data shown are repre-
sentative of at least six experiments.
Results
PCs Are Absent in the BM of NZM2410 Mice. It has been shown that
autoreactive B cells clonally expand and differentiate to produce
isotype-switched, high-affinity autoAbs, a process that mimics
normal TD B cell responses (22). Because many autoAbs
produced by lupus-prone mice are somatically mutated and
isotype-switched, it has been assumed that high levels of per-
sisting serum autoAbs are generated through the development of
long-lived PCs residing in the BM. To evaluate this hypothesis,
we determined the tissue distribution of anti-nuclear PCs from
a cohort of autoimmune mice (Fig. 1A). Measurement of
anti-DNA IgG PCs revealed high numbers of PCs in the spleens
of NZM mice, with a concordant loss of BM PCs producing
anti-DNA Abs. A similar loss of BM PCs was also observed for
histone-specific PCs in NZM mice (see Fig. 6, which is published
as supporting information on the PNAS web site, www.pnas.org).
To determine whether this dramatic loss of BM PCs in the NZM
strain was manifested in other lupus-prone strains, we evaluated
the distribution of PCs in BXSB and MRLlpr/lpr mice. Data show
that both the BXSB and MRLlpr/lpr mice have high levels of
anti-DNA PCs in the BM (Fig. 1 A). To account for potential
differences in the frequency of anti-DNA PCs among the lupus
models, and to determine whether the skewed distribution of
PCs was restricted to antiself specificities, we immunized mice
with NP-KLH to identify NP-specific PCs. Total anti-NP IgG
PCs were quantified from the spleen and BM 30 days after Ag
challenge, providing sufficient time for the migration of long-
lived PCs to the BM (Fig. 1B and refs. 5 and 23). The presence
of NP-specific PCs found almost exclusively in the spleen, but not
in the BM of NZM mice, is striking, and indicates that the paucity
of BM PCs is irrespective of Ag specificity.
Because NZM mice represent an inbred strain that has
acquired specific disease susceptibility loci from the NZB and
NZW genomes, we examined the parental strains to dissect the
genetics associated with this homing deficiency. The absence of
BM anti-DNA PCs was found to track with the NZW, rather than
with the NZB parental strain (Fig. 1C). Moreover, immunization
of mice with Ag confirmed these results, showing the presence
of splenic anti-NP PCs in NZM and NZW mice, but a lack of
Ag-specific PCs in the BM compared with NZB mice (Fig. 1D).
These findings indicate that the genetic lesion responsible for
deficient BM PCs is imparted from the NZW genome. This result
is consistent with expectations, because the NZM2410 strain has
derived 75% of its genome from NZW and 25% from NZB
mice (24).
PC migration from the spleen to the BM is especially pro-
nounced during secondary immune responses (25, 26). To
determine whether the tissue distribution of PCs in NZM mice
would change under these circumstances, ELISPOT analyses
were performed after secondary immunization. Whereas the
number of splenic Ag-specific PCs in NZM mice was significantly
elevated after rechallenge, virtually no PCs were observed in the
BM, compared with B6 controls (Fig. 2).
Accumulating PCs in the Spleen of NZM Mice Are Long-Lived and Show
Impaired CXCL12 Responsiveness. Phenotypic markers can be used
to distinguish PCs from naı̈ve and GC B cells. Expression of
CD138 is observed on differentiating PCs, but not on other
mature B cells (27–30), and is accompanied by reduced levels of
B220 expression (29, 31–33). By using three-color laser scanning
Fig. 1. PCs accumulate in the spleen but are absent in the BM of NZM mice. Spleen- and BM-derived lymphocytes from autoimmune mice were assessed for
the generation of anti-DNA IgG PCs (A and C) or NP-specific IgG PCs (B and D) from mice that were immunized with NP36-KLH CFA (immune) or CFA alone (naı̈ve)
for 30 days.
12906  www.pnas.orgcgidoi10.1073pnas.2131686100 Erickson et al.
confocal microscopy, we can identify PCs as CD138 (Fig. 3A).
Spleen sections from NZM and NZB mice revealed copious
numbers of PCs distributed throughout the red pulp, regardless
of immunization. In contrast, splenic PCs from nonautoimmune
B6 mice challenged with NP-KLH clustered in defined areas
outside B:T cell zones. It has been well established that during
TD responses, Ag-activated B cells differentiate into PCs within
the extrafollicular space of splenic red pulp (34–37). Because
many of these splenic PCs are short-lived and rapidly decline by
days 8–10 after immunization (25, 38), this result raises the
question as to whether splenic PCs in NZM mice are short- or
long-lived. To determine whether the splenic PCs were long-
lived, immune spleen cells from NZM, NZB, and B6 mice were
isolated, treated with the DNA synthesis inhibitor, Mito-C, and
adoptively transferred into Rag1/ recipients (Fig. 3B). Under
these conditions, only long-lived PCs will continue to produce Ig
due to their quiescent state (5, 23, 39). ELISPOT analysis of
recipient mice demonstrated that the majority of NZM splenic
PCs were long-lived by virtue of their resistance to Mito-C and
capacity to produce high-affinity NP-specific IgG, comprising
75% of total NP PCs. As expected, the transfer of NZM BM cells
into recipients failed to confer PCs. The slight reduction in
numbers from recipients that received inhibitor-treated cells is
likely due to the loss of short-lived PCs. In contrast, the transfer
of NZB splenic PCs revealed that the majority of these cells were
short-lived. Transfer studies using cells from nonautoimmune B6
mice immunized with NP-KLH (TD Ag) demonstrated that after
30 days the majority of long-lived PCs were found in the BM and
produced high-affinity Abs. Results from parallel experiments
using cells from B6 mice immunized with NP-Ficoll [thymus-
independent (TI) AG] demonstrated the short-lived nature of
splenic PCs by their production of low-affinity Abs, susceptibility
to Mito-C treatment and absence in the BM. The findings show
that, unlike PCs from normal mice, PCs from NZM mice
accumulate in the spleen, fail to home to the BM, and attain a
long-lived phenotype.
Changing patterns of chemokine receptor expression and
function coordinate PC emigration from the spleen to the BM.
Affinity-matured, long-lived PCs emigrate from GCs due to their
loss in chemokine responsiveness to CCL19, CCL21, and
CXCL13, which are involved in the follicular retention of mature
B cells (13, 40). In contrast, expression of CXCR4 on PCs
imparts responsiveness to CXCL12, a chemokine produced by
Fig. 2. PCs are absent in the BM of NZM mice on secondary immunization.
NP-specific ELISPOT was performed on spleen and BM cells from naı̈ve NZM and
B6 mice and those that were immunized for 30 days (1°) or rechallenged with Ags
for 30 days (2°). Total Ag-specific IgG PCs were quantified from individual organs,
with the mean (SD) values from three mice per group shown.
Fig. 3. The deficit of BM PCs in NZM mice tracks with the NZW parental strain and show aberrant chemokine responsiveness. (A) Immunohistological analysis
was performed by staining spleen cryosections with allophycocyanin (APC)-CD4, FITC-B220, and PE-CD138. The localization of CD4 T cells (blue), follicular B cells
(green), and PCs (red) are shown from naı̈ve (Left) and immune (Right) B6 and NZB mice. The accumulation of CD138B220lo PCs in the splenic red pulp of NZM
mice is evidenced by areas of yellow (Left). The exclusion of NZM PCs from B cell follicles is shown by CD4 and CD138 staining only (Right). (B) Spleen (SP) or BM
cells from TD immune NZM, NZB, and B6 mice were adoptively transferred into Rag1/ recipients. Cells from TI immune B6 mice were also transferred. As
indicated, recipients also received splenic B cells that were treated with Mito-C. Affinity maturation and long-lived nature of the transferred PCs was measured
after 30 days by performing ELISPOT on splenocytes from recipients. (C) Ex vivo chemokine migration of PCs from immune mice to the chemokines, CXCL12 and
CXCL13, was examined by flow cytofluorimetric analysis. Migrating cells were collected and stained with fluorochrome-coupled Abs to B220 and CD138. (D) The
percentage of input NP-specific IgG PCs that migrated in response to chemokine was measured from the indicated mice by performing ELISPOT on nonmigrating
cells (inserts) and those that migrated (wells).









stromal cells in the BM and is critical for homing to this organ
(13). To determine whether splenic PCs from NZM mice were
responsive to CXCL12-induced migration, ex vivo chemotaxis
assays on spleen cells from immune mice were performed. Flow
cytometric analysis of responding PCs (B220loCD138) showed
that migration of NZM PCs to CXCL12 was deficient compared
with nonautoimmune B6 controls (Fig. 3C). Moreover, this trait
segregated with NZW but not NZB PCs. Anti-NP ELISPOT
analysis was also performed to functionally assess the chemokine
responsiveness of splenic PCs (Fig. 3D). These studies confirmed
the phenotypic data showing that CXCL12-induced chemotaxis
was impaired in NZM PCs and tracked with the NZW parental
strain. These results were identical to those obtained by using
greater concentrations of CXCL12, excluding the possibility that
NZM PCs require a higher threshold of chemokine for CXCR4
signaling (see Fig. 7, which is published as supporting informa-
tion on the PNAS web site).
To verify that the impaired chemokine responsiveness of NZM
PCs was not due to differential levels of CXCR4 expression, PCs
from NZM mice were compared with B6 controls (Fig. 4A). Both
early differentiating PCs (B220hiCD138) and mature PCs
(B220loCD138) from NZM mice showed identical CXCR4
expression levels compared with B6 PCs. Sequence analysis of
the CXCR4 gene did not reveal any single-nucleotide polymor-
phisms that might confer an alteration in protein structure (data
not shown). Among the integrin family of adhesion molecules,
VLA-4 is principally expressed on mature PCs and is involved in
the retention of PCs in BM (23). Levels of VLA-4 expression
were identical between B6 and NZM PCs, indicating that the
phenotype of differentiating NZM PCs appeared normal. Mi-
gration assays further revealed that both early and mature NZM
PCs were defective in chemotaxis (Fig. 4B). Of significance,
however, is that mature naı̈ve B cells and T cells from NZM mice
were fully capable of responding to CXCL12 compared with B6
controls (Fig. 4 C and D). Thus, the inadequacy of NZM PCs to
migrate in response to CXCL12 is acquired at the early stage of
plasmacytic differentiation, is not a result of lower CXCR4
surface expression, and is selective to B lymphocytes committed
to a PC fate.
Multiple Autoimmune Susceptibility Loci Are Required for Deficient
CXCL12 Migration. Linkage studies of the NZBW, NZM2410,
MRL, and BXSB mouse models have identified multiple sus-
ceptibility loci that are critical to the development of severe lupus
nephritis (41–43). Three recessive loci strongly associated with
SLE susceptibility have been identified in the NZM2410 strain
(Sle1, Sle2, and Sle3, which are located on chromosomes 1, 4, and
7, respectively; ref. 44). B6 congenic mice carrying these sus-
ceptibility loci individually (B6.Sle1, B6.Sle2, and B6.Sle3) and
combined (B6.Sle123) have been generated (20). The tricon-
genic strain reconstitutes the autoimmune pathology of
NZM2410, whereas the single-congenic mice have only partial,
nonpathogenic phenotypes (45). A subcongenic strain
(B6.Sle1c) has also been generated that contains within its
interval the gene, Cr2, and has been shown to encode dysfunc-
tional complement receptors 1 and 2 (46). In an effort to dissect
the susceptibility interval responsible for the deficiency in BM
PCs, we performed ELISPOT analysis on each of the congenic
strains (Fig. 5 A–C). Results showed that anti-DNA PCs were
present in the spleen and BM from each of the single congenic
lines. In contrast, the tricongenic strain contained very few BM
PCs. Data from NP-KLH immune congenic mice showed similar
results for both total Ag-specific IgG PCs and high-affinity
anti-NP PCs. Chemotaxis assays revealed that splenic PCs from
single-congenic mice strongly responded to CXCL12, whereas
nominal migration was observed from tricongenic PCs (Fig. 5D).
Therefore, functional analyses of these mice show that an
individual locus does not confer impaired chemotaxis of PCs, but
Fig. 4. Deficient chemokine responsiveness to CXCL12 is restricted to B cells differentiating to a PC fate. (A) Ex vivo flow cytofluorimetric analysis was performed
on input spleen cells from immune B6 and NZM before chemotaxis assays. Cells were stained with mAbs to B220, CD138, CXCR4, and VLA4. Fluorescence intensity
of CXCR4 and VLA4 are shown on gated early differentiating PCs (B220CD138) and mature PCs (B220loCD138). (B) Migration of early and mature PCs in
response to CXCL12 and CXCL13 were quantified, based on their respective phenotype. (C and D) The selective distortion in CXCL12-induced migration of NZM
PCs was further shown by measuring the chemotaxis of mature B and CD4 T cells from identical assays. Profiles shown represent input B (B220) and T (CD4)
cells and those that migrated, in response to medium alone or chemokines. The percentage of input B and T cells that migrated in response to chemokine was
quantified by performing flow cytofluorimetric analysis on nonmigrating cells (inserts) and those that migrated (wells).
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it is the epistatic interactions of Sle1, Sle2i, and Sle3 that mediate
this deficiency.
Discussion
The specific microenvironment occupied by PCs has been im-
plicated as a determinant in cellular survival and function (2).
Accordingly, the anatomical niche that PCs occupy ultimately
controls the intensity and longevity of the humoral immune
response. This article focuses on the abnormalities observed in
the migration and function of PCs in the NZM mouse strain.
First, our data show that the inheritance of SLE susceptibility
loci results in fundamental changes in the behavior of PCs with
regard to their migratory patterns in vivo. The synergy between
these loci incapacitates the ability of postGC B cells to migrate
to the BM. Second, we show that, unlike normal splenic PCs, PCs
in the spleen of NZM mice are long-lived, establishing that the
spleen can support long-lived PCs. Third, we show that splenic
NZM PCs are unresponsive to CXCL12-induced chemotaxis.
This observation explains the basis for the inability of NZM
postGC B cells to exit the spleen. Finally, we report that resting
NZM B cells are responsive to CXCL12 migration, even though
postGC B cells are unresponsive. Thus, unresponsiveness to
CXCL12 in NZM mice is only expressed after GC activation.
PC longevity is believed to be controlled by specific survival
signals within their microenvironment. The lack of PC migration
to the BM early in life has been linked to the short duration of
humoral immunity in the newborn (47). Furthermore, the gen-
eral short-lived nature of splenic PCs is believed to be due to the
fact that the splenic red pulp does not provide the appropriate
survival signals for PC longevity (37). It must be noted that
whereas most of the PCs in the spleen are short-lived, MacClen-
nan and coworkers (37) have shown that there is a subset of
splenic PCs that are long-lived. Studies presented herein show
that the spleen can be a site that supports the survival of
long-lived PCs. It could be argued that one contribution of an Sle
loci is to change the splenic microenvironment to support PC
longevity, with this genetic trait being distinct from those genes
involved in controlling CXCL12 responsiveness. It is of interest
to note that B6.Sle3 mice appear to have an increased number
of PCs in the spleen compared with the other congenic strains,
however, whether this is due to increased B cell hyperactivity or
to increased longevity is not known. Another important issue is
that it has been suspected that CXCR4 triggering may elicit PC
longevity. Data presented here strongly argue that CXCL12 is
not an essential factor for PC longevity, because NZM PCs are
long-lived and are unresponsive to CXCL12-induced migration.
Even within the PC compartment, the issue of PC responsive-
ness to CXCL12 is complex. A number of groups have recently
shown that early PC emigrants into the BM are CXCL12-
responsive (13, 48). However, Manz and coworkers (48) have
established that there is a progressive loss of CXCL12 respon-
siveness that naturally occurs as long-lived PCs ‘‘age’’ within the
BM compartment, even though CXCR4 expression is still evi-
dent. This finding is intriguing in light of our data showing that
naı̈ve NZM B cells are responsive to CXCL12-induced migra-
tion, but postGC B cells are not responsive. Because newly
emerging PCs in the spleen of NZM mice are deficient in
CXCL12 chemotaxis, it is possible that PC precursors prema-
turely terminate responsiveness toward CXCL12. Thus, the
aging of PCs may be hyperaccelerated in NZM mice. Wakeland
and coworkers (45, 49) have recently shown that Sle1 and Sle3
confer susceptibility to lupus nephritis through hyperactivity of
B cells in the NZM2410 strain. These distinct traits of Sle1 and
Sle3 may fit with the hypothesis that terminal differentiation in
NZM mice is hyperaccelerated. Further studies using bicongenic
mice to address the role of these susceptibility loci on PC
migration are warranted.
The fact that the deficiency in CXCL12 responsiveness de-
pends on multiple Sle loci suggests that this phenotype is
associated with disease development. We have compared the
frequency of splenic and BM PCs from NZM mice ranging from
5 to 24 weeks of age to determine whether the homing properties
of PCs changes over time. Whereas results from these studies
demonstrated an increased number of splenic PCs as the mice
aged, there remained no difference in the paucity of BM PCs
regardless of Ag specificity (data not shown). Thus, at this time,
how the loss in PC homing to the BM contributes to lupus is
unclear. The discovery that PCs in the NZM model are sustained
in the spleen, but are deficient in the BM, reveals that persisting
systemic Ab responses can be achieved without the accumulation
of long-lived PCs in the BM compartment. One potential
consequence of this deficiency in the homing properties of PCs
may be preventing the natural selection of higher-affinity long-
lived PCs in the BM, thereby contributing to the loss of self-
tolerance. Recently, it has been shown that the inappropriate
distribution of B cells outside the GC may result in the loss of
censoring the development of autoreactive B lymphocytes (50).
Work by Kelsoe and coworkers (51) have shown that affinity
selection can occur outside the GC. Whereas it is clear that the
BM plays a critical role in positive and negative selection during
B cell ontogeny, the question emerges as to whether the BM also
plays a role in the censorship of affinity-matured B cells before
terminal differentiation to PCs. As linkage analyses of human
SLE have demonstrated striking similarities to the genetics of
Fig. 5. Multiple autoimmune susceptibility loci are required for distorted
chemokine responsiveness of NZM PCs. (A–C) Spleen and BM cells from B6
congenic mice that singly express the SLE susceptibility locus Sle1, Sle2, and
Sle3, or in combination, were assessed for the production of anti-DNA, total
NP, and high-affinity NP IgG-secreting PCs by ELISPOT. (D) The percentage of
input autoreactive PCs that migrated in response to chemokine was measured
from the indicated mice by performing ELISPOT as described (21).









disease susceptibility with animal models (52–55), it will be of
significant interest to learn whether defects in chemokine re-
sponsiveness is manifested by PCs in humans with lupus.
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